LivaNova (NASDAQ:LIVN) had its target price trimmed by Piper Sandler from $65.00 to $60.00 in a research note issued to investors on Wednesday morning, The Fly reports. The brokerage currently has an overweight rating on the stock.
Several other equities research analysts have also recently commented on LIVN. UBS Group cut their price target on shares of LivaNova from $70.00 to $57.00 and set a neutral rating on the stock in a research report on Thursday, April 30th. Zacks Investment Research raised shares of LivaNova from a strong sell rating to a hold rating in a research report on Thursday, May 28th. Needham & Company LLC cut their price target on shares of LivaNova from $76.00 to $68.00 and set a buy rating on the stock in a research report on Wednesday. BidaskClub cut shares of LivaNova from a hold rating to a sell rating in a research report on Friday, May 8th. Finally, Canaccord Genuity cut their price target on shares of LivaNova from $66.00 to $50.00 and set a hold rating on the stock in a research report on Thursday, April 30th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $71.00.
Shares of NASDAQ LIVN opened at $46.54 on Wednesday. The firm has a market cap of $2.26 billion, a PE ratio of -13.93, a PEG ratio of 6.61 and a beta of 0.84. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 0.51. LivaNova has a 1-year low of $33.40 and a 1-year high of $87.45. The company has a fifty day moving average price of $51.27 and a 200 day moving average price of $56.42.
In other news, Director Alfred J. Novak bought 1,000 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were bought at an average cost of $46.71 per share, with a total value of $46,710.00. Following the acquisition, the director now owns 10,570 shares in the company, valued at $493,724.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.48% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Shine Investment Advisory Services Inc. raised its holdings in LivaNova by 28.5% in the 1st quarter. Shine Investment Advisory Services Inc. now owns 898 shares of the company’s stock valued at $41,000 after acquiring an additional 199 shares during the period. Profund Advisors LLC raised its holdings in LivaNova by 6.0% in the 4th quarter. Profund Advisors LLC now owns 5,325 shares of the company’s stock valued at $402,000 after acquiring an additional 303 shares during the period. Nisa Investment Advisors LLC raised its holdings in LivaNova by 11.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,305 shares of the company’s stock valued at $159,000 after acquiring an additional 340 shares during the period. Mason Street Advisors LLC raised its holdings in LivaNova by 1.4% in the 4th quarter. Mason Street Advisors LLC now owns 25,743 shares of the company’s stock valued at $1,942,000 after acquiring an additional 365 shares during the period. Finally, Point72 Hong Kong Ltd bought a new position in LivaNova in the 4th quarter valued at about $28,000. 87.98% of the stock is currently owned by hedge funds and other institutional investors.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Further Reading: Depreciation
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.